Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
January 21st, 2020
6.3K views
Laryngotracheal stenosis results from pathologic scar deposition that critically narrows the tracheal airway and lacks effective medical therapies. Using a PLLA-PCL (70% poly-L-lactide and 30% polycaprolactone) stent as a local drug delivery system, potential therapies aimed at decreasing scar proliferation in the trachea can be studied.
Overview
This study investigates the use of drug-eluting stents in a small animal model of laryngotracheal stenosis. The protocol emphasizes a transoral placement technique that avoids open incision, making it more clinically relevant.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Medical Devices
Background
- Laryngotracheal stenosis is caused by pathological scar deposition.
- Current medical therapies for this condition are ineffective.
- Local drug delivery systems may offer new therapeutic options.
- Using genetically modified animals can enhance research outcomes.
Purpose of Study
- To explore the efficacy of PLLA-PCL stents for drug delivery.
- To develop a preclinical model for testing local therapies.
- To facilitate future investigations in larger animal models and clinical applications.
Methods Used
- Transoral intubation for stent placement.
- Induction of tracheal injury in small animals.
- Visual demonstration of surgical techniques.
- Evaluation of drug-eluting stent performance.
Main Results
- The transoral technique is less invasive and more relevant.
- Drug-eluting stents show potential for reducing scar proliferation.
- Visual aids enhance understanding of complex surgical steps.
- The model can be adapted for larger animals and clinical trials.
Conclusions
- This study provides a feasible platform for drug delivery research.
- Transoral stent placement is a promising approach for laryngotracheal stenosis.
- Future studies can build on these findings for broader applications.
Frequently Asked Questions
What is laryngotracheal stenosis?
Laryngotracheal stenosis is a condition characterized by the narrowing of the trachea due to scar tissue formation.
How does the drug-eluting stent work?
The stent releases therapeutic agents locally to reduce scar tissue formation in the trachea.
Why is the transoral technique preferred?
It minimizes invasiveness and is more clinically relevant compared to traditional open surgery.
What are the implications of this research?
This research could lead to new treatment options for patients with laryngotracheal stenosis.
Can this model be used for larger animals?
Yes, the techniques developed can be adapted for larger animal models in future studies.
What is the significance of using genetically modified animals?
Genetically modified animals can provide insights into specific biological mechanisms and responses to treatments.
Executive Industry Relevance
This method establishes a preclinical platform for evaluating localized immunomodulatory therapies in a murine model of laryngotracheal stenosis, enabling mechanistic de-risking of drug-eluting stent designs. By supporting transoral delivery and consistent drug release, it improves predictive confidence in airway fibrosis interventions prior to larger animal or clinical studies. The system facilitates target validation and assay development for antifibrotic compounds in a disease-relevant system.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses regarding local drug delivery and fibrosis modulation in airway stenosis.
- Operational Value: Supports functional target validation through biocompatible stent constructs that elicit minimal inflammatory response.
- Scientific Value: Provides a disease-relevant system to assess target engagement of immunomodulatory agents like rapamycin in vivo.
Screening & Assay Development
- Scientific Value: Delivers quantitative dependent variable measurements such as scar formation, collagen deposition, and gene expression for compound screening.
- Operational Value: Ensures assay standardization and reproducibility through standardized stent fabrication and placement protocols.
- Scientific Value: Enables reliable compound evaluation via measurable reductions in fibrosis and immune cell infiltration.
Translational & Preclinical Research
- Scientific Value: Connects discovery through preclinical validation by demonstrating stent-mediated reduction in tracheal scar formation over 21 days.
- Operational Value: Addresses risk-adjusted advancement decisions by providing survival, histology, and molecular readouts post-stent placement.
- Scientific Value: Focuses on predictive de-risking by validating biocompatibility and drug elution consistency under physiological conditions.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical evaluation, supporting iterative refinement of drug-eluting stent formulations.
- Discovery Biology: Explains how the method supports hypothesis testing of local immunomodulation and pathway clarification in fibrotic airway remodeling.
- Screening: Describes assay readiness through standardized stent production (28–30 h) and transoral placement enabling high-throughput cohort studies.
- Analytics: Highlights measurements such as quantitative real-time PCR, ELISA, immunohistochemistry, and survival analysis that help compare stent performance across conditions.
- Translational Research: Connects the method to preclinical continuity by demonstrating biocompatibility and antifibrotic efficacy in vivo, supporting advancement to larger models.
- Enterprise Reuse: Frames the stent fabrication process as a reusable platform for testing multiple antifibrotic or immunomodulatory agents beyond rapamycin.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target modulation, reduction of mechanistic ambiguity in fibrosis pathways, and validation of local drug delivery efficacy.
- Operational Value: Standardization, reproducibility, and scalability of stent manufacturing and surgical placement across cohorts.
- Strategic Value: Better go/no-go decisions, capital efficiency through early failure detection, and reduced late-stage biological risk in airway therapeutic development.
- Portfolio Impact: Risk-adjusted prioritization of compounds based on antifibrotic potency and local delivery efficiency in a clinically relevant model.
Implementation Considerations
- Required scientific expertise in polymer chemistry, surgical techniques, and histopathological analysis.
- Instrumentation and analytical infrastructure needs including vacuum hoods, angiocatheters, qPCR, ELISA, and immunohistochemistry systems.
- Cross-team standardization requirements between pharmacology, pathology, and surgical teams for consistent stent placement and outcome assessment.
- Adaptation considerations across model systems, including scaling stent dimensions and adjusting surgical access for larger species.
- Practical limitations supported by source material: risk of stent collapse with excessive tracheal pressure, need for atraumatic manipulation to avoid airway obstruction, and solvent handling requirements for dichloromethane.
Biopharma FAQs
Why does stent placement pressure matter for target validation in LTS models?
Excessive pressure during stent placement can cause tracheal collapse, leading to airway obstruction and animal death, which compromises data integrity. Proper placement ensures stent patency and reliable assessment of drug elution and tissue response. This technical consideration is critical for generating valid preclinical outcomes in fibrosis studies.
How does Bleomycin-induced injury isolation support discovery pipeline objectives?
The Bleomycin-coated wire brush induces controlled tracheal injury to model pathologic scar formation, enabling consistent LTS induction across animals. This isolation of the injury variable allows researchers to attribute changes in fibrosis to the stent-delivered drug rather than procedural variability. It supports mechanistic de-risking by providing a reproducible disease model for target validation.
What quantitative dependent variable measurements enable lead identification in stent studies?
Quantitative outcomes include scar formation assessment, collagen deposition levels, gene expression via qPCR, and immune cell infiltration via immunohistochemistry and flow cytometry. These measurements provide objective, comparable readouts to evaluate the antifibrotic efficacy of eluted agents like rapamycin. They enable data-driven lead identification and prioritization in preclinical programs.
Why do replication requirements matter for cross-functional collaboration in stent development?
Replication across large cohorts is enabled by the 28–30 hour stent manufacturing process, which ensures consistent supply for reproducible experiments. Standardized transoral placement and injury induction protocols allow pharmacology, pathology, and surgical teams to align on shared endpoints. This reproducibility supports reliable data transfer between discovery and translational teams.
What statistical analysis capabilities are required before implementing stent-based drug delivery studies?
Implementation requires capabilities for survival analysis, comparative gene expression (qPCR), protein quantification (ELISA), and histological scoring (immunohistochemistry) to assess stent biocompatibility and drug efficacy. These analyses enable statistical comparison between treated and control groups to determine significant reductions in fibrosis. Such capabilities are essential for validating preclinical findings and informing go/no-go decisions.
Chapters in this video
0:04
Title
1:19
Rapamycin Preparation in Poly (l-lactide)-poly (epsilon-caprolatcone) (PLLA-PCL)
1:56
Rapamycin-Eluting PLLA-PCL Murine Airway Stent Creation
3:08
Laryngotracheal Stenosis Induction
4:50
Transoral PLLA-PCL Stent Placement
5:45
Histologic Sample Preparation
6:26
Results: Representative Tracheal Stent Biocompatibility Assessment
7:23
Conclusion
